Protean PTEN: form and function.

Pten regulates neuronal arborization and social interaction in mice. Neuron (2006) 6.11

Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci (2010) 3.73

PTEN function: how normal cells control it and tumour cells lose it. Biochem J (2004) 3.06

The tuberous sclerosis complex. Ann N Y Acad Sci (2010) 2.51

A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. Proc Natl Acad Sci U S A (2008) 2.34

PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling. EMBO J (2006) 2.16

Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet (2003) 1.94

Mutation screening of the PTEN gene in patients with autism spectrum disorders and macrocephaly. Am J Med Genet B Neuropsychiatr Genet (2007) 1.65

Regeneration of diabetic axons is enhanced by selective knockdown of the PTEN gene. Brain (2014) 1.64

The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res (2009) 1.62

Interfacial kinetic analysis of the tumour suppressor phosphatase, PTEN: evidence for activation by anionic phospholipids. Biochem J (2003) 1.59

Differential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndrome. Am J Hum Genet (2008) 1.59

Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Mol Cell Biol (2005) 1.55

Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: Involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs. Mol Biol Cell (2006) 1.38

PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer (2010) 1.38

DNA methylation in endometrial cancer. Epigenetics (2010) 1.32

Alteration of phosphatidylinositol 3-kinase cascade in the multilobulated nuclear formation of adult T cell leukemia/lymphoma (ATLL). Proc Natl Acad Sci U S A (2005) 1.25

Contiguous gene deletion within chromosome arm 10q is associated with juvenile polyposis of infancy, reflecting cooperation between the BMPR1A and PTEN tumor-suppressor genes. Am J Hum Genet (2006) 1.24

Phosphatase and tensin homologue (PTEN) regulates synaptic plasticity independently of its effect on neuronal morphology and migration. J Physiol (2011) 1.24

STRADalpha deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice. J Clin Invest (2010) 1.23

Genetic disruption of Pten in a novel mouse model of tomaculous neuropathy. EMBO Mol Med (2012) 1.17

The differential diagnosis of familial lentiginosis syndromes. Fam Cancer (2011) 1.12

Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets. Adv Anat Pathol (2008) 1.11

Genetics of skin appendage neoplasms and related syndromes. J Med Genet (2005) 1.08

The lentiginoses: cutaneous markers of systemic disease and a window to new aspects of tumourigenesis. J Med Genet (2005) 1.07

Natural compounds from traditional medicinal herbs in the treatment of cerebral ischemia/reperfusion injury. Acta Pharmacol Sin (2010) 1.02

Selective deletion of PTEN in dopamine neurons leads to trophic effects and adaptation of striatal medium spiny projecting neurons. PLoS One (2009) 1.00

Distinct expression profiles for PTEN transcript and its splice variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome. Am J Hum Genet (2006) 1.00

Hereditary hamartomatous polyposis syndromes: understanding the disease risks as children reach adulthood. Gastroenterol Hepatol (N Y) (2010) 0.99

Polygenic susceptibility to breast cancer: current state-of-the-art. Future Oncol (2009) 0.98

Functions and Regulation of the PTEN Gene in Colorectal Cancer. Front Oncol (2014) 0.97

Distinct functional outputs of PTEN signalling are controlled by dynamic association with β-arrestins. EMBO J (2011) 0.97

PTEN inhibits BMI1 function independently of its phosphatase activity. Mol Cancer (2009) 0.97

PTEN encoding product: a marker for tumorigenesis and progression of gastric carcinoma. World J Gastroenterol (2003) 0.96

Trail resistance induces epithelial-mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer. PLoS One (2014) 0.91

Genetic control of postnatal human brain growth. Curr Opin Neurol (2016) 0.91

Gastrointestinal polyposis with esophageal polyposis is useful for early diagnosis of Cowden's disease. World J Gastroenterol (2008) 0.90

PTEN mutation, methylation and expression in breast cancer patients. Oncol Lett (2013) 0.90

MicroRNA-21 regulates hTERT via PTEN in hypertrophic scar fibroblasts. PLoS One (2014) 0.89

Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer. World J Gastroenterol (2004) 0.89

The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. Cancer Biol Ther (2011) 0.89

Growth, invasion, metastasis, differentiation, angiogenesis and apoptosis of gastric cancer regulated by expression of PTEN encoding products. World J Gastroenterol (2003) 0.88

Dysregulated mTORC1-Dependent Translational Control: From Brain Disorders to Psychoactive Drugs. Front Behav Neurosci (2011) 0.88

Critical role of neuronal pentraxin 1 in mitochondria-mediated hypoxic-ischemic neuronal injury. Neurobiol Dis (2012) 0.87

Beta catenin and cytokine pathway dysregulation in patients with manifestations of the "PTEN hamartoma tumor syndrome". BMC Med Genet (2012) 0.87

Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology. J Mol Diagn (2008) 0.86

Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer. Therap Adv Gastroenterol (2012) 0.86

Pten regulates collective cell migration during specification of the anterior-posterior axis of the mouse embryo. Dev Biol (2012) 0.86

Downregulation of PTEN at corneal wound sites accelerates wound healing through increased cell migration. Invest Ophthalmol Vis Sci (2011) 0.86

Cowden syndrome: mucocutaneous lesions as precursors of internal malignancy. Oral Maxillofac Surg (2014) 0.85

Therapeutic Implications of Targeting AKT Signaling in Melanoma. Enzyme Res (2011) 0.85

The PTEN tumor suppressor gene and its role in lymphoma pathogenesis. Aging (Albany NY) (2015) 0.84

High-expression of DJ-1 and loss of PTEN associated with tumor metastasis and correlated with poor prognosis of gastric carcinoma. Int J Med Sci (2013) 0.84

Gene expression in breastmilk cells is associated with maternal and infant characteristics. Sci Rep (2015) 0.84

Posttranslational regulation of phosphatase and tensin homolog (PTEN) and its functional impact on cancer behaviors. Drug Des Devel Ther (2014) 0.83

AKT activation promotes PTEN hamartoma tumor syndrome-associated cataract development. J Clin Invest (2013) 0.82

Multiple primary malignancies and subtle mucocutaneous lesions associated with a novel PTEN gene mutation in a patient with Cowden syndrome: case report. BMC Med Genet (2011) 0.82

PTEN knockdown alters dendritic spine/protrusion morphology, not density. J Comp Neurol (2014) 0.82

PTEN mediates the antioxidant effect of resveratrol at nutritionally relevant concentrations. Biomed Res Int (2014) 0.82

Negative Regulation of Receptor Tyrosine Kinase (RTK) Signaling: A Developing Field. Biomark Insights (2007) 0.82

PPARgamma, PTEN, and the Fight against Cancer. PPAR Res (2008) 0.82

Prognostic impact of gastrointestinal bleeding and expression of PTEN and Ki-67 on primary gastrointestinal stromal tumors. World J Surg Oncol (2014) 0.82

FH535 inhibited metastasis and growth of pancreatic cancer cells. Onco Targets Ther (2015) 0.81

Differential expression of PTEN gene correlates with phenotypic heterogeneity in three cases of patients showing clinical manifestations of PTEN hamartoma tumour syndrome. Hered Cancer Clin Pract (2013) 0.81

The molecular genetics of breast cancer and targeted therapy. Biologics (2007) 0.81

Characterization of EN-1078D, a poorly differentiated human endometrial carcinoma cell line: a novel tool to study endometrial invasion in vitro. Reprod Biol Endocrinol (2007) 0.81

Curcumin cytotoxicity is enhanced by PTEN disruption in colorectal cancer cells. World J Gastroenterol (2013) 0.81

Down-regulation of PTEN expression due to loss of promoter activity in human hepatocellular carcinoma cell lines. World J Gastroenterol (2005) 0.81

PTEN gene: a model for genetic diseases in dermatology. ScientificWorldJournal (2012) 0.81

Long-term consequences of conditional genetic deletion of PTEN in the sensorimotor cortex of neonatal mice. Exp Neurol (2016) 0.79

Cowden syndrome-related mutations in PTEN associate with enhanced proteasome activity. Cancer Res (2013) 0.79

Role of PTEN in modulation of ADP-dependent signaling pathways in vascular endothelial cells. Biochim Biophys Acta (2013) 0.79

PTEN-mediated Akt activation in human neocortex during prenatal development. Histochem Cell Biol (2005) 0.79

The protein phosphatase activity of PTEN is essential for regulating neural stem cell differentiation. Mol Brain (2015) 0.79

Loss and reduced expression of PTEN correlate with advanced-stage gastric carcinoma. Exp Ther Med (2012) 0.79

Classification, molecular characterization, and the significance of pten alteration in leiomyosarcoma. Sarcoma (2012) 0.78

The Phosphoinosotide 3-Kinase Catalytic Subunit p110α is Required for Normal Lens Growth. Invest Ophthalmol Vis Sci (2016) 0.78

ComiRNet: a web-based system for the analysis of miRNA-gene regulatory networks. BMC Bioinformatics (2015) 0.78

PRL-3 promotes the peritoneal metastasis of gastric cancer through the PI3K/Akt signaling pathway by regulating PTEN. Oncol Rep (2016) 0.77

Significance of Survivin and PTEN expression in full lymph node-examined gastric cancer. World J Gastroenterol (2006) 0.77

The genomics of colorectal cancer: state of the art. Curr Genomics (2008) 0.76

Systematic investigation into the role of intermittent high glucose in pancreatic beta-cells. Int J Clin Exp Med (2015) 0.75

Bioinformatic prediction of ultraviolet light mutagenesis sensitivity of human genes and a method for genetically engineering UVB resistance. Cancer Inform (2011) 0.75

Clinical guideline seom: hereditary colorectal cancer. Clin Transl Oncol (2015) 0.75

Does PTEN gene mutation play any role in Li-Fraumeni syndrome. Med J Islam Repub Iran (2016) 0.75

Low expression of phosphatase and tensin homolog in clear‑cell renal cell carcinoma contributes to chemoresistance through activating the Akt/HDM2 signaling pathway. Mol Med Rep (2015) 0.75

Structural mutation analysis of PTEN and its genotype-phenotype correlations in endometriosis and cancer. Proteins (2016) 0.75

PTEN insufficiency modulates ER+ breast cancer cell cycle progression and increases cell growth in vitro and in vivo. Drug Des Devel Ther (2015) 0.75

Involvement of IGF-2, IGF-1R, IGF-2R and PTEN in development of human tooth germ - an immunohistochemical study. Organogenesis (2016) 0.75

Hereditary Syndromes Manifesting as Endometrial Carcinoma: How Can Pathological Features Aid Risk Assessment? Biomed Res Int (2015) 0.75

Aggressive juvenile polyposis in children with chromosome 10q23 deletion. World J Gastroenterol (2013) 0.75

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 29.34

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem (1998) 17.36

Cellular survival: a play in three Akts. Genes Dev (1999) 17.05

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet (1997) 15.38

Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell (1998) 13.98

Pten is essential for embryonic development and tumour suppression. Nat Genet (1998) 13.41

Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet (1997) 10.71

A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature (1998) 10.35

AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature (2000) 8.35

Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A (1999) 7.88

Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet (1998) 7.36

Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science (1998) 7.08

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A (2001) 6.99

The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A (1998) 6.98

Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science (1998) 6.62

Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell (1999) 6.59

High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol (1998) 6.38

Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet (2001) 6.36

The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains. FASEB J (2000) 6.26

TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res (1997) 5.92

Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol (2001) 5.80

Regulation of PTEN transcription by p53. Mol Cell (2001) 5.44

P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A (1997) 5.32

Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol (2000) 5.22

C2-domains, structure and function of a universal Ca2+-binding domain. J Biol Chem (1998) 5.01

Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet (1998) 4.72

Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet (1997) 4.39

Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat Genet (1997) 4.27

The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem (2001) 4.00

Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet (1997) 3.56

Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet (1996) 3.53

Phosphatidylinositol 3-kinase. Bioessays (1994) 3.27

High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res (2000) 3.24

PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet (1999) 3.22

Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet (2000) 3.12

The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci U S A (1999) 3.10

PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci U S A (1998) 3.05

Proteus syndrome: diagnostic criteria, differential diagnosis, and patient evaluation. Am J Med Genet (1999) 3.02

The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet (1986) 2.78

Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet (2001) 2.77

Molecular cloning, sequencing, and mapping of EGR2, a human early growth response gene encoding a protein with "zinc-binding finger" structure. Proc Natl Acad Sci U S A (1988) 2.73

The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol (2001) 2.71

Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci U S A (2000) 2.65

Ras signalling and apoptosis. Curr Opin Genet Dev (1998) 2.63

Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol (2000) 2.27

Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene (2001) 2.25

Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet (1998) 2.17

Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proc Natl Acad Sci U S A (2001) 2.17

Mutations of the human PTEN gene. Hum Mutat (2000) 2.11

Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel membrane-associated guanylate kinase. J Biol Chem (2000) 2.09

Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. J Cell Biol (2001) 2.09

PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem (1999) 2.07

Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol (2000) 2.05

Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int J Cancer (2002) 2.02

Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. Am J Hum Genet (1997) 1.94

Molecular classification of the inherited hamartoma polyposis syndromes: clearing the muddied waters. Am J Hum Genet (1998) 1.92

Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet (1999) 1.92

PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet (2001) 1.87

PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res (1999) 1.85

Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol (1998) 1.85

Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis. Hum Mol Genet (2000) 1.84

Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol (2001) 1.83

Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci U S A (2001) 1.82

Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes. Am J Hum Genet (2001) 1.81

Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res (2000) 1.79

Protein modules as organizers of membrane structure. Curr Opin Cell Biol (1999) 1.77

Deletion of PTEN in a patient with Bannayan-Riley-Ruvalcaba syndrome suggests allelism with Cowden disease. Am J Med Genet (1997) 1.74

Bannayan-Riley-Ruvalcaba syndrome. Am J Med Genet (1992) 1.69

PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model. Hum Mol Genet (2001) 1.69

Profiling the downstream genes of tumor suppressor PTEN in lung cancer cells by complementary DNA microarray. Am J Respir Cell Mol Biol (2000) 1.67

Gab1 acts as an adapter molecule linking the cytokine receptor gp130 to ERK mitogen-activated protein kinase. Mol Cell Biol (1998) 1.66

Genetics of Cowden syndrome: through the looking glass of oncology. Int J Oncol (1998) 1.63

PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Hum Mol Genet (2001) 1.56

A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor. J Biol Chem (2000) 1.56

Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res (1998) 1.52

Germline PTEN mutations in Cowden syndrome-like families. J Med Genet (1998) 1.51

A role for nuclear PTEN in neuronal differentiation. J Neurosci (2000) 1.50

Exclusion of PTEN and 10q22-24 as the susceptibility locus for juvenile polyposis syndrome. Cancer Res (1997) 1.47

PTEN germ-line mutations in juvenile polyposis coli. Nat Genet (1998) 1.45

Cowden syndrome. J Med Genet (1995) 1.45

A novel germline mutation of the PTEN gene in a patient with macrocephaly, ventricular dilatation, and features of VATER association. J Med Genet (2001) 1.40

The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases. Am J Hum Genet (1997) 1.37

The tumor suppressor PTEN negatively regulates insulin signaling in 3T3-L1 adipocytes. J Biol Chem (2000) 1.35

PTEN mutations are uncommon in Proteus syndrome. J Med Genet (2001) 1.35

Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN. Cancer Res (2001) 1.32

Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. J Med Genet (2001) 1.26

Germline PTEN mutation in a family with Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome. Am J Med Genet (1998) 1.24

PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein. Oncogene (1999) 1.19

Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet (2001) 1.17

Transduction pathways involved in Hypoxia-Inducible Factor-1 phosphorylation and activation. Free Radic Biol Med (2001) 1.16

PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene (2000) 1.15

A gene for familial juvenile polyposis maps to chromosome 18q21.1. Am J Hum Genet (1998) 1.12

Adenovirus-mediated gene transfer of MMAC1/PTEN to glioblastoma cells inhibits S phase entry by the recruitment of p27Kip1 into cyclin E/CDK2 complexes. Cancer Res (1999) 1.11

Genetic heterogeneity in familial juvenile polyposis. Cancer Res (2000) 1.10

Phospholipid signalling in the nucleus. Een DAG uit het leven van de inositide signalering in de nucleus. Biochim Biophys Acta (1998) 1.08

Cowden syndrome (multiple hamartoma syndrome). Dermatol Clin (1995) 1.06

Phosphatidylinositol 3-kinase in HL-60 nuclei is bound to the nuclear matrix and increases during granulocytic differentiation. Biochem Biophys Res Commun (1998) 1.05

Identification of a PTEN mutation in a family with Cowden syndrome and Bannayan-Zonana syndrome. J Am Acad Dermatol (2001) 1.02

Mutations of PTEN in patients with Bannayan-Riley-Ruvalcaba phenotype. J Med Genet (1998) 1.01

Cowden disease. Report of a family and review. Ann Genet (1996) 0.96

Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid (2009) 10.20

Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med (2002) 6.94

Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell (2007) 6.52

Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med (2007) 6.47

Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89

Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA (2004) 4.52

Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA (2006) 4.09

Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet (2002) 3.89

Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res (2008) 3.41

Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res (2012) 3.33

Validation of proposed DSM-5 criteria for autism spectrum disorder. J Am Acad Child Adolesc Psychiatry (2011) 2.72

Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res (2006) 2.70

Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA (2005) 2.69

Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet (2007) 2.64

Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA (2005) 2.59

A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet (2010) 2.59

PTEN hamartoma tumor syndrome: an overview. Genet Med (2009) 2.44

Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet (2003) 2.43

Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. JAMA (2010) 2.36

The nuclear affairs of PTEN. J Cell Sci (2008) 2.34

From developmental disorder to heritable cancer: it's all in the BMP/TGF-beta family. Nat Rev Genet (2003) 2.26

Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. Surgery (2008) 2.26

PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol (2002) 2.16

Hamartomatous polyposis syndromes. Nat Clin Pract Gastroenterol Hepatol (2007) 2.16

Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer (2006) 2.13

A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab (2006) 2.10

Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int J Cancer (2002) 2.02

SNP arrays in heterogeneous tissue: highly accurate collection of both germline and somatic genetic information from unpaired single tumor samples. Am J Hum Genet (2008) 2.00

A time study of cancer genetic counselors using a genetic counselor-only patient care model versus a traditional combined genetic counselor plus medical geneticist care model. J Natl Compr Canc Netw (2013) 2.00

Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. Am J Hum Genet (2008) 1.96

Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology (2010) 1.96

Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet (2003) 1.94

APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci U S A (2002) 1.89

Highly penetrant hereditary cancer syndromes. Oncogene (2004) 1.84

Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes. Am J Hum Genet (2012) 1.84

Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis. Cancer Res (2005) 1.84

Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 1.78

Combined total genome loss of heterozygosity scan of breast cancer stroma and epithelium reveals multiplicity of stromal targets. Cancer Res (2004) 1.76

Frequency of germline genomic homozygosity associated with cancer cases. JAMA (2008) 1.67

Unusual features in a patient with neurofibromatosis type 1: multiple subcutaneous lipomas, a juvenile polyp in ascending colon, congenital intrahepatic portosystemic venous shunt, and horseshoe kidney. Am J Med Genet A (2004) 1.67

Prospective comparison of family medical history with personal genome screening for risk assessment of common cancers. Eur J Hum Genet (2012) 1.62

Genomic instability within tumor stroma and clinicopathological characteristics of sporadic primary invasive breast carcinoma. JAMA (2007) 1.60

Differential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndrome. Am J Hum Genet (2008) 1.59

Multiple endocrine neoplasia type 2: an overview. Genet Med (2011) 1.58

Genetics of carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors. J Clin Endocrinol Metab (2007) 1.57

BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels. Hum Mol Genet (2003) 1.54

Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int J Cancer (2006) 1.53

Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res (2009) 1.53

Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology (2013) 1.49

PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene (2004) 1.49

Frequent epigenetic inactivation of the SLIT2 gene in gliomas. Oncogene (2003) 1.47

Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. Am J Hum Genet (2003) 1.41

Cowden syndrome. Semin Oncol (2007) 1.39

Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation. Am J Hum Genet (2007) 1.39

Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clin Cancer Res (2009) 1.38

Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am J Pathol (2004) 1.37

The pressure rises: update on the genetics of phaeochromocytoma. Hum Mol Genet (2002) 1.36

Defining phenotypes and cancer risk in hyperplastic polyposis syndrome. Dis Colon Rectum (2011) 1.36

Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma. Cancer Res (2007) 1.34

Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev (2006) 1.33

Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein. Cancer Res (2005) 1.33

Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. J Clin Oncol (2013) 1.33

Total-genome analysis of BRCA1/2-related invasive carcinomas of the breast identifies tumor stroma as potential landscaper for neoplastic initiation. Am J Hum Genet (2006) 1.31

Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis. Am J Respir Crit Care Med (2009) 1.30

The approach to the patient with paraganglioma. J Clin Endocrinol Metab (2009) 1.30

Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Res Treat (2009) 1.26

Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone. Int J Cancer (2006) 1.26

Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. J Clin Endocrinol Metab (2011) 1.25

Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model. Eur J Hum Genet (2011) 1.25

Contiguous gene deletion within chromosome arm 10q is associated with juvenile polyposis of infancy, reflecting cooperation between the BMPR1A and PTEN tumor-suppressor genes. Am J Hum Genet (2006) 1.24

Evidence of MEN-2 in the original description of classic pheochromocytoma. N Engl J Med (2007) 1.24

Microenvironmental genomic alterations and clinicopathological behavior in head and neck squamous cell carcinoma. JAMA (2007) 1.24

Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with G0-G1 in MCF-7 cells. Cancer Res (2003) 1.24

Renal cancer in von Hippel-Lindau disease and related syndromes. Nat Rev Nephrol (2013) 1.23

Extra-adrenal and adrenal pheochromocytomas associated with a germline SDHC mutation. Nat Clin Pract Endocrinol Metab (2008) 1.22

Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab (2005) 1.20

Unregulated smooth-muscle myosin in human intestinal neoplasia. Proc Natl Acad Sci U S A (2008) 1.20

Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53. Hum Mol Genet (2011) 1.19

PTEN autoregulates its expression by stabilization of p53 in a phosphatase-independent manner. Cancer Res (2006) 1.19

When overgrowth bumps into cancer: the PTEN-opathies. Am J Med Genet C Semin Med Genet (2013) 1.18

Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol (2010) 1.17

Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol (2004) 1.16

Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models. Cancer Res (2009) 1.15

Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility. Clin Endocrinol (Oxf) (2003) 1.14

Large germline deletions of mitochondrial complex II subunits SDHB and SDHD in hereditary paraganglioma. J Clin Endocrinol Metab (2004) 1.14

Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. J Clin Endocrinol Metab (2005) 1.14

The ERK1/2 pathway modulates nuclear PTEN-mediated cell cycle arrest by cyclin D1 transcriptional regulation. Hum Mol Genet (2006) 1.13

Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Hum Mutat (2011) 1.12

PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway. Hum Mol Genet (2002) 1.11

Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer. Hum Mol Genet (2006) 1.11

Autism spectrum disorders as a qualitatively distinct category from typical behavior in a large, clinically ascertained sample. Assessment (2009) 1.10

A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC Cancer (2006) 1.10

Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res (2012) 1.10

Microbiomic subprofiles and MDR1 promoter methylation in head and neck squamous cell carcinoma. Hum Mol Genet (2011) 1.09

A founding locus within the RET proto-oncogene may account for a large proportion of apparently sporadic Hirschsprung disease and a subset of cases of sporadic medullary thyroid carcinoma. Am J Hum Genet (2002) 1.09

Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome. J Clin Endocrinol Metab (2009) 1.09

Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany. Nephrol Dial Transplant (2013) 1.08

Functioning paraganglioma and gastrointestinal stromal tumor of the jejunum in three women: syndrome or coincidence. Am J Surg Pathol (2006) 1.08

High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. J Clin Oncol (2005) 1.08